Pieris Achieves Milestone Payment In Daiichi Sankyo, Inc. (4568.t) Collaboration To Develop Anticalin® Therapeutics
6/23/2014 8:51:22 AM
FREISING, Germany--(BUSINESS WIRE)--Pieris AG announced that it has achieved a second milestone for its second program, and fifth milestone overall, in its discovery and development collaboration with Daiichi Sankyo Company Limited (hereinafter Daiichi Sankyo; headquartered in Chuo Ward, Tokyo, TSE 4568), triggering an undisclosed payment. The milestone is based on successful in vitro and in vivo studies validating a range of Anticalin® targeted protein drug candidates designed to bind a Daiichi Sankyo target. With this achievement, Pieris will transfer development responsibility of the program to Daiichi Sankyo, who will initiate further in vivo studies in non-human primates.
Help employers find you! Check out all the jobs and post your resume.
comments powered by